52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
I-Mab Says Selling Shareholders May Offer, From Time To Time, Up To 25.1 Million Ordinary Shares
Morphosys, I-Mab Gets FDA Clearance Of Ind Application For Mor210/Tj210 In Patients With Advanced Cancer
Morphosys, I-Mab Announce FDA Clearance For Mor210/Tj210 In Patients With Advanced Cancer
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
Biotechnology & Drugs
WILLOW HOUSE, Floor 4
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* SAYS POTENTIAL VALUE OF SUCH LICENSE OF THE 2 BISPECIFIC PROGRAMS IS A MINIMUM $1 BILLION IN UPFRONT AND MILESTONE PAYMENTS- CONF. CALL
U.S. drugmaker AbbVie Inc will pay $180 million in upfront payment to develop and sell Chinese biotech company I-Mab's cancer drug, the companies said on Friday.
Drugmaker AbbVie Inc has entered an agreement to develop and sell Chinese biotech company I-Mab's lead cancer drug, the companies said on Friday.
* I-MAB AND ABL BIO TO PRESENT PRECLINICAL DATA FOR JOINT BISPECIFIC ANTIBODY PROGRAM AT THE 2020 AMERICAN ASSOCIATION FOR CANCER RESEARCH VIRTUAL MEETING II Source text for Eikon: Further company coverage:
* I-MAB REPORTS INTERIM RESULTS FROM PART 1 STUDY FOR ANTI-GM-CSF ANTIBODY TJM2 TO TREAT COVID-19 PATIENTS WITH -CYTOKINE RELEASE SYNDROME
* I-MAB AND GENEXINE ANNOUNCE CHINA NMPA CLEARANCE FOR PHASE 2 CLINICAL TRIAL OF TJ107/HYLEUKIN-7™ IN GLIOBLASTOMA MULTIFORME
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.